Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PragmaTIL: IL-2 analog (ANV419/ANV600) vs high-dose IL-2 after TIL therapy in advanced solid tumors
2023-506400-99-00Phase 2Authorised
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Jul 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of ANV419, ANV600, aldesleukin and autologous tumor-infiltrating lymphocytes in cutaneous melanoma (CM), non-small cell lung cancer (NSCLC) and Cervical Cancer (CC) (3 arms), sponsored by Vall d'Hebron Institute of Oncology. Primary endpoints: Mean number of predefined grade ≥3 relevant adverse events and Change in PRO-CTCAE composite score of selected symptoms. Planned start Jul 2024; status: authorised.
02
Drugs
ANV419ANV600aldesleukinautologous tumor-infiltrating lymphocytes
03
Conditions
cutaneous melanoma (CM)non-small cell lung cancer (NSCLC)Cervical Cancer (CC)
Beyond the preview
Go deeper on 2023-506400-99-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506400-99-00.